gastrointestinal tumours, non-colorectal

Annals of Oncology 25 (Supplement 4): iv210–iv253, 2014
doi:10.1093/annonc/mdu334.25
gastrointestinal tumours,
non-colorectal
640P
MOLECULAR PORTRAIT OF RESECTED GASTRIC CANCER
(RGC) WITH NEXT GENERATION SEQUENCING (NGS)
ACCORDING TO A CLINICAL BIOLOGICAL RISK MODEL
CONSIDERING FHIT, APC AND HER-2 OVEREXPRESSION
KRAS
PI3KCA
TP53
MET
SMAD4
STK11
Good
Poor
p-value
8 (38.1%)
8 (38.1%)
6 (28.6%)
2 (9.5%)
1 (4.8%)
1 (4.8%)
1 (7.7%)
2 (15.4%)
3 (23.1%)
1 (7.7%)
2 (15.4%)
2 (15.4%)
0.11
0.25
0.99
0.99
0.54
0.54
ATM, CDKN2A, EGFR, ERBB2, FBXW7, SMARCB1, were mutated in 2 cases, while
FGFR3, IDH1, JAK3, KIT, NOTCH1, NRAS, PTEN, in 1.
Conclusions: These exploratory findings suggest that NGS technologies with
formalin-fixed and paraffin embedded tissues may potentially help to drive future
customized therapies for RGC, and deserve to be prospectively tested together with
clinical parameters in the context of larger samples.
Disclosure: All authors have declared no conflicts of interest.
abstracts
Aim: FHIT, APC and HER-2 have recently shown to powerfully complement clinical
factors to significantly discriminate prognosis for RGC. Additional genetic alterations
potentially driving both outcome and treatment may be concurrently screened with
NGS multigene analysis.
Methods: On the bases of a internally validated model (Bria E, Ann Oncol 2013),
tumor blocks from 114 intestinal-histology patients at Good (2-yrs Cancer Specific
Table: 640P
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: [email protected].
Downloaded from http://annonc.oxfordjournals.org/ by guest on January 23, 2015
E. Bria1, M. Fassan2, S. Pilotto1, G. De Manzoni3, S. Kinspergher1, I. Sperduti4,
U. Peretti1, M. Simbolo2, P. Capelli5, A. Tomezzoli6, C. Luchini5, A. Mafficini2,
G. Turri2, G. Tortora7, A. Scarpa8
1
Medical Oncology, Azienda Ospedaliera Universitaria Integrata Verona-"Borgo
Roma", Verona, ITALY
2
Pathology, ARC-NET Applied Research on Cancer Center, Verona, ITALY
3
Surgical Oncology, Azienda Ospedaliera Universitaria Integrata Verona-"Borgo
Roma", Verona, ITALY
4
Biostatistics, Regina Elena National Cancer Institute, Roma, ITALY
5
Pathology, Azienda Ospedaliera Universitaria Integrata Verona-"Borgo Roma",
Verona, ITALY
6
Pathology and Diagnostics, University of Verona, Verona, ITALY
7
Oncologia Medica, Azienda Ospedaliera Universitaria Integrata Verona-"Borgo
Roma", Verona, ITALY
8
Patologia e Diagnostica, Anatomia Patologica, Azienda Ospedaliera Universitaria
Integrata Verona-Borgo Roma, Verona, ITALY
Survival 89.7% and Overall Survival 84.8%) and Poor prognosis (CSS 7.3% and OS
<1%) were analyzed for mutations in 50 cancer-associated genes using multiplex PCR
amplification of DNA from microdissected paraffin samples and the Ion AmpliSeq
Cancer Panel (Life Technologies).
Results: Forty-two patients displayed to be Good and Poor prognostic performers at
both CSS and OS; 34 patients (80.9%) were evaluable for NGS analysis. Patients’
characteristics: Good (N = 21; male/female: 13/8; grading: 1-2/3: 9/12; median F.U.:
70.8; median CSS not reached; 10-yrs CSS: 58.9%; median OS: 115.0 [95% CI 33-197];
10-yrs OS: 45.9%); Poor (N = 13, male/female: 9/4; grading: 1-2/3: 6/7; median F.U.:
10.8; median CSS and OS 7.0 [95% CI 2-12]; 1-yr CSS/OS: 7.7%). A significant
difference between Good and Poor patients was found for median age ( p = 0.021),
resected nodes ( p = 0.018), and positive node-ratio ( p<0.0001). Seventeen (Good/Poor:
14/3), 11 (Good/Poor: 5/6) and 6 (Good/Poor: 2/4) RGC contained multiple, single or
none gene alteration, respectively. The most frequently mutated genes (>3) follows:

Download Report